Abstract
Pleural effusion is a common presentation for many pulmonary and systemic diseases, particularly heart failure, pneumonia, cancer and tuberculosis (TB). An estimated 1.5 million people develop a pleural effusion each year in the United States alone (1). Despite the prevalence of the disease, research in pleural medicine has attracted far less attention than that of much rarer respiratory conditions. Advances in pleural diseases are desperately lacking and far fewer than in other common pulmonary diseases. One paradigmatic example is the use of talc pleurodesis which was first reported in 1935 (2), but remains the standard therapy for symptomatic malignant pleural effusion in most centers. Few, if any, diseases in medicine are now managed in the same way as they were in the 1930’s.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
